ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…
Category: News
This Gender Logs More Eye Surgeries in Residency
Records from more than 4800 ophthalmology residents show the average number of cataract surgeries and other eye procedures could vary by gender and race or ethnicity. Medscape Medical News
ARVO Attendees Hear Call to Save National Eye Institute
An eye research advocacy group has issued an urgent plea to thwart proposals to gut federal funding for biomedical research and dismantle the National Eye Institute. Medscape Medical News
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today…
How Climate Change Threatens Eye Health
Cataracts, pink eye, and other ocular disorders are linked to heat, air pollution, and higher UV exposure. Knowable Magazine
Cataract Surgery May Be Safe Beyond A1c Cutoffs
Cataract surgery may not increase the risk for postoperative endophthalmitis or severe systemic adverse events in patients with diabetes, regardless of A1c levels, according to a recent study. Medscape Medical News
MHRA Approves First UK Treatment for Thyroid Eye Disease
The Medicines and Healthcare products Regulatory Agency has approved teprotumumab, the first treatment to be licensed in the UK for adults with thyroid eye disease. Medscape News UK
$7.22 Bn OTC Artificial Tears Market Size, Share Analysis, Growth Trends and Forecasts 2024-2025 & 2033 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “OTC Artificial Tears Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033” report has been added to ResearchAndMarkets.com’s offering. The OTC Artificial Tears market is expected to grow from US$ 4….
Vision Care Market Forecast Report and Company Analysis 2025-2033 Featuring Essilor, J&J, Bausch Health, Novartis, Grand Vision, Carl Zeiss, Valeant Pharma, Paragon Vision Science, and Menicon – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Vision Care Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033” report has been added to ResearchAndMarkets.com’s offering. The Vision Care Market is anticipated to rise at a compound annual growt…
Warby Parker Announces First Quarter 2025 Results
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the first quarter ended March 31, 2025. “Our team deliver…
LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects
SEATTLE–(BUSINESS WIRE)– #DryAMD–LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects Treated with Valeda
Amgen’s TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom
CAMBRIDGE, England–(BUSINESS WIRE)–Today, Amgen announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for TEPEZZA® (teprotumumab) as the first therapy specifically licensed for the trea…
Alcon Announces Results of 2025 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon Announces Results of 2025 Annual General Meeting
Alcon Announces Results of 2025 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon Announces Results of 2025 Annual General Meeting
Breakthrough Gene Therapies Poised to Transform Cone Rod Dystrophy Treatment Landscape – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Cone Rod Dystrophy Market: Analysis By Type, By Treatment Type, By End User, By Region Size and Trends – Forecast up to 2030” has been added to ResearchAndMarkets.com’s offering. As of 2024, the global cone rod dystrophy m…
OcuSciences Announces FDA Marketing Clearance of OcuMet Beacon in Retinal Health Assessment at ARVO
ANN ARBOR, Mich.–(BUSINESS WIRE)–OcuSciences, Inc., a leader in advanced ocular diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its flagship device, the OcuMet Beacon, proprietary, non-invasive …
Oral, Injected Semaglutide May Pose Distinct Eye Risks
The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which also identified differences based on sex, age, and timing of onset. Medscape Medical News
Glaukos Announces First Quarter 2025 Financial Results
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financ…
AAN 2025: The Impact of Updated Diagnostic Criteria in RRMS
Dr Pavan Bhargava comments on the practical implications of the revised diagnostic criteria, which allow for earlier diagnosis. Medscape
Bausch + Lomb Announces First-Quarter 2025 Results
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2025 financial results. “Our core business is pe…